Navigation Links
ResMed Announces Deferred Conversions in Connection With Stock Split
Date:8/13/2010

SYDNEY, Aug. 12 /PRNewswire-FirstCall/ -- ResMed, Inc. (NYSE: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

As advised in the Company's 6 August announcement:

  • Stockholders of record on the New York Stock Exchange at the close of trading on August 17, 2010 will receive one additional share of common stock for each share held on that date.  The common stock will be distributed to shareholders on or about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer and Trust Company, LLC.  The common stock is expected to begin trading on a post-split basis on the NYSE beginning on August 31, 2010, or one day following the distribution date.
  • Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange will also receive a bonus issue of one additional CDI for every CDI held on the ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX: RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX: RMDBN).  The bonus CDIs will be distributed by ResMed's ASX share registry, Computershare Limited, on or about August 31, 2010, and normal trading will begin on the following day.

Due to the difference in market practice between the NYSE and ASX, ResMed applied for and has been granted a waiver of rules 13.9.4  and 13.9.9 of the ASX Settlement Operating Rules, allowing it to defer the processing of conversions (transmutations) between its Common Stock and CDI registers that are lodged in the period from and including 12 August 2010 up to and including 31 August 2010.  Therefore, no conversions (transmutations) will be processed during this time. Processing of conversions will re-commence on 1 September 2010.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders.  The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed, Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited, Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.


'/>"/>
SOURCE ResMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. to Present at Upcoming Conferences
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Acquires Laboratoires Narval
5. Trubion Announces Dates for Second-Quarter and First-Half 2010 Earnings Conference Call
6. Mylan Announces Completion of Add-On Offering of Senior Notes
7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
8. ProUroCare Medical Inc. Announces Completion of Warrant Replacement Offering
9. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
10. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
11. Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):